Kleo Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kleo Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11105
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kleo Pharmaceuticals Inc (Kleo Pharmaceuticals) is a biotechnology company that develops small molecules in the field of immunotherapy to emulate biologics. The company provides adaptable technology platforms such as antibody recruiting molecules (ARMs) and synthetic antibody mimics (SyAMs) designed to direct your immune system to fight specific disease causing cells. It is developing new immunotherapies that can be deployed against cancer and infectious diseases. Kleo Pharmaceuticals works in collaboration with PeptiDream Inc to develop oncology immunotherapies. The company operates in the US. Kleo Pharmaceuticals is headquartered in New Haven, Connecticut, the US.

Kleo Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kleo Pharma Raises USD21 Million in Series B Financing 10
Kleo Pharma Raises USD13.5 Million in Venture Financing 11
Kleo Pharma Raises Funds through Series A Financing 12
Partnerships 13
PeptiDream and Kleo Pharma Enter into Co-Development Agreement 13
Licensing Agreements 14
Kleo Pharma Enters into Licensing Agreement with Yale University 14
Kleo Pharmaceuticals Inc – Key Competitors 15
Kleo Pharmaceuticals Inc – Key Employees 16
Kleo Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Apr 03, 2018: Kleo Pharmaceuticals Appoints Luca Rastelli, PhD as Chief Scientific Officer 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kleo Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kleo Pharma Raises USD21 Million in Series B Financing 10
Kleo Pharma Raises USD13.5 Million in Venture Financing 11
Kleo Pharma Raises Funds through Series A Financing 12
PeptiDream and Kleo Pharma Enter into Co-Development Agreement 13
Kleo Pharma Enters into Licensing Agreement with Yale University 14
Kleo Pharmaceuticals Inc, Key Competitors 15
Kleo Pharmaceuticals Inc, Key Employees 16

List of Figures
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kleo Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kleo Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Orezone Gold Corporation:企業の戦略・SWOT・財務情報
    Orezone Gold Corporation - Strategy, SWOT and Corporate Finance Report Summary Orezone Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Japan Airlines Co Ltd
    Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Airlines Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Orchid Pharma Ltd (ORCHIDPHAR):企業の財務・戦略的SWOT分析
    Summary Orchid Pharma Ltd (Orchid), formerly Orchid Chemicals & Pharmaceuticals Ltd is a pharmaceutical company that develops and manufactures pharmaceutical solutions such as formulations and API products. The company offers formulations such as cardiovascular products, neuropsychiatry products, an …
  • IHI Corporation (7013)-エネルギー分野:企業M&A・提携分析
    Summary IHI Corporation (IHI) is a heavy machinery engineering group. It provides technology oriented products and services to customers in the public, private and industrial sectors across the world. The group designs and manufactures a diverse range of products including ships and offshore facilit …
  • Sui Northern Gas Pipelines Ltd (SNGP):企業の財務・戦略的SWOT分析
    Sui Northern Gas Pipelines Ltd (SNGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Tufts Medical Center:医療機器:M&Aディール及び事業提携情報
    Summary Tufts Medical Center (TMC), formerly New England Medical Center Hospital Inc, a subsidiary of Tufts University School of Medicine, is an academic medical center that provides patient care services. The center offers treatments for brain tumor, breast cancer, cardiac arrhythmia, cardiomyopath …
  • Maruishi Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Maruishi Pharmaceutical Co Ltd (Maruishi) is a pharmaceutical company that develops and sells medical drugs. The company offers products in the fields of perioperative and infection control. Its products include anesthetics, perioperative drugs, pharmacopoeia drugs, and disinfectants and ant …
  • Humanigen Inc (HGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Humanigen Inc(Humanigen) formerly known as KaloBios Pharmaceuticals Inc, is a development stage biopharmaceutical company that develops medicines for neglected and rare diseases. The company offers benznidazole, a nitroimidazole derivative used for the treatment of Chagas disease, a parasiti …
  • Slovnaft AS (1SLN01AE):企業の財務・戦略的SWOT分析
    Slovnaft AS (1SLN01AE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Numaligarh Refinery Ltd:企業の戦略的SWOT分析
    Numaligarh Refinery Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • American Express Company:企業のM&A・事業提携・投資動向
    American Express Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's American Express Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • 3i Group Plc:企業のM&A・事業提携・投資動向
    3i Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's 3i Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Operation Technology Inc:企業の戦略的SWOT分析
    Operation Technology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • J. Lauritzen AS:石油・ガス:M&Aディール及び事業提携情報
    Summary J. Lauritzen AS (J. Lauritzen), a subsidiary of Lauritzen Fonden, is a shipping company that provides ocean transport services. The company operates a fleet of bulk carriers and gas carriers. Its bulk carriers include ocean transport services for dry bulk cargoes. J. Lauritzen provides marit …
  • Las Vegas Sands Corp:戦略・SWOT・企業財務分析
    Las Vegas Sands Corp - Strategy, SWOT and Corporate Finance Report Summary Las Vegas Sands Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Energen Corporation:企業の戦略・SWOT・財務情報
    Energen Corporation - Strategy, SWOT and Corporate Finance Report Summary Energen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Virgin Media Inc.:企業の戦略的SWOT分析
    Virgin Media Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Clinigen Group Plc (CLIN):企業の財務・戦略的SWOT分析
    Summary Clinigen Group Plc (Clinigen Group) is a pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supply. The company acquires and licenses essential commercial medicines such as foscavir, cardioxane, ethyol, savene and vibativ. It off …
  • Re-Vana Therapeutics Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Re-Vana Therapeutics Ltd (Re-Vana) is an ocular pharmaceutical and drug delivery company that develops and commercialization of biodegradable long- acting drug delivery platforms to treat ophthalmic conditions. The company provides drug delivery products such as OcuLief, an injectable platfo …
  • Kyushu Financial Group Inc (7180):企業の財務・戦略的SWOT分析
    Kyushu Financial Group Inc (7180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆